Get the Stockscreener App
1.62
0.93%
0.01
Ocugen Inc stock is traded at $1.62, with a volume of 3.68M.
It is up +0.93% in the last 24 hours and up +17.75% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.61
Open:
$1.55
24h Volume:
3.68M
Relative Volume:
0.72
Market Cap:
$530.39M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-6.00
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
-16.24%
1M Performance:
+17.75%
6M Performance:
+57.77%
1Y Performance:
+166.31%
1-Day Range:
$1.55
$1.68
1-Week Range:
$1.55
$2.00
52-Week Range:
$0.515
$2.00
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.6204 | 526.99M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.24 | 116.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.84 | 80.33B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
727.36 | 44.42B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
316.72 | 42.53B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.60 | 33.32B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen, Inc. honors women leaders advancing gene therapy innovation - Traders Union
Is Ocugen Inc. (2H51) stock worth buying before Fed actionInsider Selling & Free High Return Stock Watch Alerts - Naître et grandir
Will Ocugen Inc. stock continue upward momentumTrade Exit Report & AI Optimized Trade Strategies - Naître et grandir
Employee dedication drives gene therapy progress, Ocugen, Inc. asserts - Traders Union
Ocugen’s Growing Pains: High Execution and Compliance Risks Threaten Shareholder Value - TipRanks
Ocugen (NASDAQ:OCGN) Trading Down 7.2%Here's Why - MarketBeat
OCGN Analyst Rating Maintained by Chardan Capital at Buy with $7 - GuruFocus
Ocugen (NASDAQ:OCGN) Receives "Buy" Rating from Chardan Capital - MarketBeat
Ocugen, Inc. Hits New 52-Week High of $2.00, Marking Major Milestone - Markets Mojo
Ocugen, Inc. (NASDAQ:OCGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Ocugen Posts Wider FY25 Loss, Advances Gene Therapy And Vaccine Pipeline - Nasdaq
Ocugen Q4 2025 Earnings Call Transcript - MarketBeat
Ocugen 2025 Financial Results: Quarterly and Annual ReportNews and Statistics - IndexBox
Ocugen (OCGN) Q4 2025 Earnings Call Transcript - The Globe and Mail
Ocugen files petition in Delaware court to validate share increase amendment - Investing.com Nigeria
Ocugen (OCGN) Advances Gene Therapy Trials and Strengthens Leade - GuruFocus
Ocugen (NASDAQ:OCGN) Shares Gap DownWhat's Next? - MarketBeat
Ocugen (OCGN) Reports Q4 Earnings and Cash Position Update - GuruFocus
Ocugen, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results - Ocugen, Inc.
Ocugen 10-K: Revenue $4.4M, Net Loss $67.8M - TradingView
Ocugen (NASDAQ: OCGN) advances RP, GA and Stargardt gene therapies - Stock Titan
Ocugen Seeks Court Validation of Charter Amendment Dispute - TipRanks
Ocugen (NASDAQ:OCGN) Announces Earnings Results - MarketBeat
Court petition over Ocugen (NASDAQ: OCGN) share increase vote - Stock Titan
Ocugen (NASDAQ: OCGN) advances eye gene therapies and extends cash runway - Stock Titan
Ocugen, Inc. completes OCU400 Phase 3 and secures first OCU400 licensing deal amid leadership boost - Traders Union
Earnings call transcript: Ocugen Q4 2025 reveals steady R&D investment By Investing.com - Investing.com Nigeria
Ocugen Q4 Earnings Call Highlights - Yahoo Finance
OCGN: Advanced gene therapy pipeline, strong clinical data, and extended cash runway into late 2026 - TradingView
Ocugen reports Q4 EPS (6c), consensus (6c) - TipRanks
OCGN: OCU400 Phase 3 enrollment completed; strong pipeline progress and extended cash runway - TradingView
Ocugen (OCGN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Ocugen (OCGN) Achieves Significant Milestones in 2025 - GuruFocus
OCUGEN ($OCGN) Releases Q4 2025 Earnings - Quiver Quantitative
OCGN: Advanced gene therapy pipeline and secured financing, extending cash runway into late 2026 - TradingView
Ocugen Completes Enrollment in OCU400 Phase 3 Clinical Trial for Retinitis Pigmentosa, Prepares for Major 2027 Data Announcements - Quiver Quantitative
Earnings Summary: Ocugen Q4 - Benzinga
BRIEF-Ocugen Q4 EPS USD -0.06 - TradingView
OCGN Earnings History & Surprises | EPS & Revenue Results | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen: Fourth Quarter Financial Results Overview - Bitget
Examining the Future: Ocugen's Earnings Outlook - Benzinga
OCGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Ocugen (NASDAQ:OCGN) Sets New 1-Year HighStill a Buy? - MarketBeat
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Key facts: Ocugen completes patient enrollment for OCU400 trial; 6-cent loss per share expected - TradingView
Ocugen announces enrollment for Phase 3 liMeliGhT trial is complete - TipRanks
Ocugen completes enrollment in phase 3 retinitis pigmentosa trial - Investing.com
Ocugen Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Ocugen (OCGN) Completes Enrollment for Phase 3 OCU400 Trial - GuruFocus
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):